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Purpose: We aimed to verify the current status of transurethral resection of the prostate 
(TURP) in Korea.
Materials and Methods: The medical records of 1,341 men who underwent TURP in 
9 Korean medical centers between 2004 and 2008 were reviewed. The patients were 
divided into two groups according to time periods: 2004-2005 (group 1) and 2006-2008 
(group 2). To verify differences in the two patient groups, age, prostate volume, in-
dications for TURP, preoperative International Prostate Symptom Score (IPSS), and 
resected tissue weight were evaluated. 
Results: The mean age of the patients was 71.2 years and the mean IPSS was 22.7. The 
patients’ characteristics were not significantly different between the two groups. The 
annual cases of TURP increased over the study period. The proportion of lower urinary 
tract symptoms (LUTS) as an indication for TURP increased up to 58.3% in group 2 
compared with 51.6% in group 1 (p=0.019). However, the proportion of patients who 
presented with acute urinary retention decreased from 35.5% to 30.3% with marginal 
statistical significance (p=0.051). Other indications such as hematuria, bladder stone, 
recurrent urinary tract infection, and hydronephrosis were not significantly different 
between the groups. The mean resected weights of the prostate were similar (17.5 g 
in group 1 and 18.3 g in group 2, respectively; p＞0.05).
Conclusions: TURP has been steadily performed in patients with benign prostatic hy-
perplasia and it is expected to remain constant. LUTS was the most common indication 
for TURP in recent years.
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INTRODUCTION
For many decades, transurethral resection of the prostate 
(TURP) has been considered the gold standard surgical 
treatment for lower urinary tract symptoms (LUTS), acute 
urinary retention (AUR), recurrent infection, hematuria, 
and azotemia resulting from benign prostatic hyperplasia 
(BPH) [1]. Despite the efficacy and safety of pharmacother-
apy, the surgical management of BPH is still recommended 
in certain conditions, including the presence of refractory 
urinary retention, bladder stone, persistent gross hema-
turia, recurrent urinary tract infection, or renal insuffi-
ciency secondary to BPH [2].
　Although TURP remains an effective treatment, 15% to 
20% of patients develop significant complications, and 10% 
to 15% require a second intervention within 10 years [3]. 
To improve safety outcomes, a number of minimally inva-
sive surgical techniques have been developed for the treat-Korean J Urol 2011;52:406-409
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FIG. 1. Annual cases of transurethral resection of prostate in 9 
medical centers Linear regression showed No.=40.8 x year−b. 
(p=0.026, R-square=0.85).
TABLE 1. Characteristics of the patients who underwent TURP
Characteristics Group 1 Group 2 Total p-value
No. of TURP 420 921 1,341 -
Age (yr) 71.9±7.3 70.8±7.7 71.2±7.6 0.016
IPSS 23.4±8.0 22.4±8.1 22.7±8.1 0.092
PSA 5.28±6.36 5.62±6.65 5.51±6.56 0.372
TPV 56.7±25.7 58.4±28.9 57.8±28.0 0.334
Resected weight 17.5±13.4 18.3±14.0 18.0±13.8 0.381
Data presented with standard deviation. IPSS: International Pro-
state Symptom Score, PSA: prostate-specific antigen, TPV: total
prostate volume, TURP: transurethral resection of prostate
TABLE 2. Indications for TURP in the time periods analyzed
Indications
No. (%)
p-value
Group 1 Group 2 Total
Lower urinary tract
symptoms
222 (52.9) 540 (58.8) 762 (57.0) 0.041
Mild to moderate
(IPSS＜20)
  46 (25.6) 154 (35.6) 200 (32.6) 0.016
a
Severe 
(IPSS≥20)
134 (74.4) 279 (64.4) 413 (67.4)
Acute urinary 
retention
153 (36.4) 289 (31.5) 442 (33.0) 0.051
Hematuria 26 (6.2) 53 (5.8) 79 (5.9)  ＞0.05
Bladder stone 12 (2.9) 28 (2.0) 30 (2.2)  ＞0.05
Recurrent urinary 
tract infection
  2 (0.5) -   2 (0.1)  ＞0.05
Hydronephrosis   1 (0.3)   3 (0.3)   4 (0.3)  ＞0.05
Others   4 (1.0) 15 (1.6) 19 (1.4)  ＞0.05
TURP: transurethral resection of prostate, IPSS: International 
Prostate Symptom Score, 
a: chi-square statistical analysis be-
tween the mild to moderate symptom group and the severe symp-
tom group
ment of LUTS related to BPH, such as needle ablation, elec-
trovaporization, vaporization resection, holmium laser, ul-
trasound, and microwave therapy [4]. Moreover, the intro-
duction of medical therapy has brought about significant 
changes in the management of patients with moderate to 
severe LUTS [5]. In the era of medical therapy, TURP 
seems to be performed less frequently in patients with 
symptomatic BPH. The objective of this study was to assess 
the current status of TURP for BPH in Korea.
MATERIALS AND METHODS
The medical records of 1,341 men who underwent TURP 
in 9 medical centers between 2004 and 2008 were reviewed. 
Patients were eligible for inclusion only if their primary 
reason for TURP was BPH. Patients undergoing open pros-
tatectomy were not included in this surgical analysis. 
Patients were excluded if they underwent TURP for carci-
noma of the prostate or if their postoperative pathology was 
not compatible with a BPH diagnosis. The patients were 
divided into two groups according to the time periods in 
which they underwent TURP: 2004-2005 (group 1) and 
2006-2008 (group 2). To verify the differences in the two pa-
tient groups, the parameters of age, prostate volume, in-
dications for TURP, preoperative International Prostate 
Symptom Score (IPSS), and resected tissue weight were 
evaluated. The symptom severity of the patients was div-
ided into two categories by IPSS as mild to moderate (IPSS
＜20) and severe (IPSS≥20). Preoperative prostatic vol-
ume was measured by transrectal ultrasound. The weight 
of the resected chips was documented from the pathology 
report.
　Statistical analysis was performed by using the Student’s 
t-test and chi-square test for categorical variables and a lin-
ear regression analysis for continuous variables. Results 
were considered significant at p＜0.05.
RESULTS
A total of 1,341 patients were identified with an average 
age of 71.2 years (range, 41-94 years). The average IPSS 
was 22.7. The baseline characteristics of the patients in-
cluding IPSS, prostate volume, and serum prostate-specif-
ic antigen (PSA) were similar between the groups. The 
mean age of group 1 was 71.9 years, which was older than 
that of group 2 (Table 1).
　The annual cases of TURP increased over the study peri-
od (Fig. 1). The proportion of LUTS as an indication for 
TURP increased up to 58.3% in group 2 compared with 
51.6% in group 1 (p=0.041). Also, the proportion of patients 
who underwent TURP for severe LUTS significantly de-
creased from 74.4% in group 1 to 64.4% in group 2, respec-
tively (p=0.016). However, the proportion of patients who 
presented with AUR decreased from 35.5% to 30.3% with 
marginal statistical significance (p=0.051). The number of 
patients who suffered from hematuria, bladder stone, re-
current urinary tract infection, and hydronephrosis before 
their TURP was not significantly different between the 
time periods (Table 2).Korean J Urol 2011;52:406-409
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　The average weight of the resected prostate was 18.0 g 
(range, 1.5-90 g). Over the study period, similar mean wei-
ghts of the prostate were resected (17.5 g in group 1 and 18.3 
g in group 2; p＞0.05).
DISCUSSION
Two decades ago, we did not frequently offer medical ther-
apy to patients with symptomatic LUTS associated with 
BPH, but rather recommended TURP as the primary mode 
of treatment. Over the course of the past two decades, medi-
cal therapy has become the standard first-line therapy for 
symptomatic LUTS associated with BPH. The increasing 
use of other minimally invasive treatment modalities, such 
as ablation, evaporation, and enucleation technique with 
laser, has led to a decline in TURP [6,7]. An American study 
reported a 43% decrease in cases of TURP between 1987 
and 1994 [6], and this decline has also been observed in 
Europe [8]. Enthusiastic reports on the success of alter-
native treatment options represented by ‘minimally in-
vasive treatment’ in the urological press seemed to herald 
the end of TURP as the gold standard, perhaps best re-
flected by Stamey’s quote that ‘TURP is now a therapy of 
history’ [6]. In our study, however, contrary to other re-
ports, the annul number of TURP procedures for BPH in-
creased during the mid 2000s, despite other treatment mo-
dalities for BPH. One possible explanation for this increas-
ing annual number of TURP procedures during the mid 
2000s is the high prevalence of BPH in aged men and the 
continuously growing number of elderly men with BPH 
who needed surgical treatment. The other explanation is 
that the urologists participating in this study, to whom 
minimally invasive modalities were not available, per-
formed TURP enthusiastically. Considering these facts, 
the overall proportion of TURP might be decreasing.
　The proportion of TURP owing to BPH-related sympto-
matic LUTS in the current study increased over the time 
period. Several series of studies have demonstrated that 
medical treatment for patients with symptomatic BPH 
with an α-adrenergic antagonist and 5-α reductase in-
hibitors could lower the risk of AUR and recurrent gross 
hematuria [8-10]. It was our hypothesis that a trial of medi-
cal therapy that ended in failure may increase this propor-
tion. In several previous studies, similar observations were 
reported. In 1990, 2% of patients undergoing TURP had 
previously been on prostatic medical therapy, and this pro-
portion was increased up to 17% in 2000 [11]. In 57.0% of 
our patients, TURP was performed because of significant 
LUTS, which was the most common indication. Borboroglu 
et al reported that 80.9% of patients had significant LUTS 
preoperatively [12]. However, a controversial result was 
reported that TURP was performed in only 29.5% of pa-
tients with symptoms of prostatism [3]. These differences 
might be due to many factors, including public awareness 
about the disease, accessibility to medical care, widespread 
use of pharmacological agents as alternative therapy, and 
the health care system of each country. Although the exact 
number of patients taking pharmacological agents before 
TURP was not evaluated in our study, the majority might 
receive some form of medication for BPH before TURP.
　There was a trend for the proportion of patients under-
going TURP because of AUR to decrease over the time peri-
od in the current study. We can attribute this observation 
to reduced needs for surgery by a voiding trial without cath-
eter and medical treatment. However, in England, over a 
10-year study between 1990 and 2000, the proportion of pa-
tients who underwent TURP for urinary retention in-
creased from 33% to 58%, which has become the most com-
mon indication of TURP, whereas LUTS as an indication 
of TURP decreased from 65% to 42% [11]. Preoperatively, 
33.0% of patients presented with AUR, which is still a 
somewhat higher rate than those reported in previous 
studies (15.2% to 27.1%) [3,12]. McConnell et al and 
Roehrborn et al demonstrated a lower rate of AUR in pa-
tients given medical therapy (α-adrenergic antagonist 
and/or 5-α reductase inhibitors) than in those given place-
bo [8,13,14]. This could be another explanation for the ten-
dency for the proportion of patients who underwent TURP 
for AUR to decrease in our study.
　The low incidence of recurrent gross hematuria as an in-
dication for TURP (5.9%) compared to the study of Mebust 
et al (12.0%) in the era of no acceptable medical therapy for 
BPH could be due to the widespread use of medical therapy 
[3]. Finasteride has been shown to be effective for the treat-
ment of BPH-related recurrent gross hematuria in more 
than 90% of treated patients [12,15].
　The incidence of obstructive uropathy, as evidenced by 
the presence of hydronephrosis, was only 0.3% in our study. 
BPH-related renal insufficiency as an indication for TURP 
was under 1% in most studies [12,15]. This low incidence 
of obstructive uropathy could result from early access to 
medical care nowadays.
　Because of the increasing use of pharmacological ther-
apy in the management of BPH-related LUTS, TURP 
would be deferred. Also, delay in surgical therapy results 
in the progression of BPH.
　Patients treated by TURP show an increase in not only 
prostate volume but also resected prostate volume, which 
may be because the surgery was delayed by treatment with 
α-1 blockers or 5-α reductase inhibitors [16]. 
　As a result, it is supposed that larger glands would be re-
sected in the era of medical therapy for BPH. The average 
weight of the resected prostate tissue in this study was 18.0 
g, which was comparable to that in other reports (18.8-37 
g) [3,12,17,18]. However, the resected prostate volume was 
not significantly different between the groups in the pres-
ent study. 
　The mean age of the patients in group 1 was older than 
in group 2. This means that we consider TURP as a pre-
emptive treatment in the era of medical therapy for BPH.
　Meanwhile, among patients with LUTS (IPSS≥20) as 
an indication for TURP, severe LUTS decreased from 74.4% 
in group 1 to 64.4% in group 2. This might be explained by 
the operators’ active trial or patients’ increased request for Korean J Urol 2011;52:406-409
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TURP during this period.
　This multicenter study of 5-years’ experience with TURP 
is obviously limited by the retrospective nature and the 
short time period in which changes in the indication for 
TURP were evaluated. Moreover, because the 9 institutions 
involved in this study do not represent Korean urological 
society, the incidence of TURP may not be generalizable. 
Also, the effect of the minimally invasive procedures and 
medical therapy for BPH was not considered in this study. 
Because the prevalence of BPH is increasing in the Korean 
population, the proportion of TURP among the treatment 
options for BPH might have decreased relatively. However, 
we could see a temporal treatment status of TURP.
CONCLUSIONS
In the mid-2000s, TURP was steadily performed in pa-
tients with BPH and it is expected to remain constant. The 
proportion of TURP as a treatment for symptomatic BPH- 
related LUTS has increased. These changes seemed to co-
incide with the increasing use of medical therapy as a first- 
line treatment for LUTS associated with BPH. TURP is 
still considered as an effective surgical intervention for 
BPH and as such is expected to be constantly performed 
even in the era of medical therapy and minimally invasive 
therapy for BPH.
Conflicts of Interest
The authors have nothing to disclose.
REFERENCES
1. Fitzpatrick JM. Minimally invasive and endoscopic management 
of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Novick 
AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 9th 
ed. Phliladelphia: Saunders; 2007;2803-44.
2. AUA Practice Guideline Committee. AUA guideline on manage-
ment of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis 
and treatment recommendations. J Urol 2003;170:530-47.
3. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transure-
thral prostatectomy: immediate and postoperative complication. 
A cooperative study of 13 participating institutions evaluating 
3,885 patients. J Urol 1989;141:243-7.
4. Son H, Song SH, Paick JS. Current laser treatments for benign 
prostatic hyperplasia. Korean J Urol 2010;51:737-44.
5. O’Leary MP. Treatment and pharmacologic management of BPH 
in the context of common comorbidities. Am J Manag Care 2006; 
12(5 Suppl):S129-40.
6. Madersbacher S, Marberger M. Is transurethral resection of the 
prostate still justified? BJU Int 1999;83:227-37.
7. Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE. 
Benign prostatic hyperplasia in Sweden 1987 to 1994: changing 
patterns of treatment, changing patterns of costs. Urology 1997; 
50:214-9.
8. McConnell JD, Brukewitz R, Walsh P, Andriole G, Lieber M, 
Holtgrewe HL, et al. The effect of finasteride on the risk of acute 
urinary retention and the need for surgical treatment among men 
with benign prostatic hyperplasia. Finasteride Long-Term 
Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
9. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzo-
sin for treatment of benign prostatic hypertrophy. The BPH-ALF 
Group. Lancet 1991;337:1457-61.
10. Miller MI, Puchner PJ. Effects of finasteride on hematuria asso-
ciated with benign prostatic hyperplasia: long-term follow-up. 
Urology 1998;51:237-40. 
11. Wilson JR, Urwin GH, Stower MJ. The changing practice of tran-
surethral prostatectomy: a comparison of cases performed in 1990 
and 2000. Ann R Coll Surg Engl 2004;86:428-31.
12. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. 
Immediate and postoperative complications of transurethral 
prostatectomy in the 1990s. J Urol 1999;162:1307-10.
13. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, 
Nandy I, et al. The effects of combination therapy with dutas-
teride and tamsulosin on clinical outcomes in men with sympto-
matic benign prostatic hyperplasia: 4-year results from the 
CombAT study. Eur Urol 2010;57:123-31.
14. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, 
Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, fi-
nasteride, and combination therapy on the clinical progression of 
benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
15. Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, 
Harpster LE. The treatment of gross hematuria secondary to pro-
static bleeding with finasteride. J Urol 1998;159:1232-3.
16. Shin YS, Park JK. Changes in surgical strategy for patients with 
benign prostatic hyperplasia: 12-year single-center experience. 
Korean J Urol 2011;52:189-93.
17. Horninger W, Unterlechner H, Strasser H, Bartsch G. Transure-
thral prostatectomy: mortality and morbidity. Prostate 1996;28: 
195-200.
18. Estey EP, Mador DR, McPhee MS. A review of 1486 transurethral 
resections of the prostate in a teaching hospital. Can J Surg 1993; 
36:37-40.